• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International symposium on bioanalytical chemistry >Affinity Chromatography of Pharmaceutical Compound as Ligand for the Purification of Protein
【24h】

Affinity Chromatography of Pharmaceutical Compound as Ligand for the Purification of Protein

机译：药物化合物作为配体的亲和层析，用于纯化蛋白质

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The unique advantages of affinity chromatography as a bioselective purification procedure have been shown considerably attractive. This approach is realized by covalently attaching a specific ligand that interacts with the desired molecule to an insoluble inert support. It is important that the ligands chosen for the specific interaction should reflect rational reliability in practical process. Conventionally, the ligand can be a substrate, inhibitor, antibody, antigen, cofactor, hormone or an analogue of any of these. The problems arisen from the ligands are difficult purification, microoganism, solvent or pH sensitivity that bring about degradation of ligand and shortage of affinity column life. In the purification process of biotechnology the ligand is sometimes harmful when it is mixed into a pharmaceutical product. A new kind of ligand, a small molecular pharmaceutical compound, was firstly studied as an affinity chromatographic ligand for the purification of proteins. Among the compounds 4-amino-N(5-methyl-3-isoxazolyl)-benzenesulfonamide(AMIBSA) was chosen as a ligand to investigate its affinity bioselectivity.
机译：作为生物选择性净化程序的亲和色谱作为生物选择性净化程序的独特优点已经显着。通过共价连接特定配体来实现这种方法，其与所需分子相互作用至不溶性惰性载体。重要的是，为特定相互作用选择的配体应该反映实际过程中的合理可靠性。通常，配体可以是底物，抑制剂，抗体，抗原，辅因子，激素或其中任何一个的类似物。来自配体中出现的问题是难以纯化，微阴影，溶剂或pH敏感性，其带来配体的降解和亲和柱寿命的短缺。在生物技术的纯化过程中，当将其混合到药物产品中时，配体有时有害。首先研究了一种新的配体，一种小分子药物化合物作为亲和色谱配体，用于纯化蛋白质。在化合物中，选择4-氨基-N（5-甲基-3-异恶唑基） - 苯磺酰胺（Amibsa）作为配体，以研究其亲和力生物选择性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号